How PMOS gets diagnosed

If you have a PCOS diagnosis, or you are trying to get one, what you are diagnosing is now formally called PMOS (polyendocrine metabolic ovarian syndrome), the new name confirmed by global consensus in May 2026. The diagnostic criteria did not change. The clinical condition did not change. The 2023 International Evidence-based Guideline (Teede et al.) is still the anchor that defines who has PMOS and who does not.

This is a care-prep guide. It walks through the diagnostic framework, the labs and exclusions a complete workup includes, the places diagnosis tends to go wrong, and what to ask for if your workup has been partial or you have already been dismissed. It is meant to be read before the appointment and brought into it.

The average person with PMOS waits more than two years and sees three or more clinicians before getting a diagnosis. That delay is not because the criteria are obscure. They are public, were rewritten in 2023 to be clearer, and take less than a page to summarise. The delay happens because the criteria get routinely misapplied: clinicians order the wrong labs, weight the wrong findings, and lean on stereotypes the Guideline explicitly rejects. Walking in with a specific ask is one of the most reliable ways to shorten the path.

Step 1: Know the two-of-three framework

For an adult diagnosis under the 2023 Guideline, you need at least two of three features, after other causes have been excluded:

1. Clinical or biochemical hyperandrogenism. Clinical means visible androgenic signs (hirsutism, jawline acne, androgenic alopecia). Biochemical means measurable elevations in total testosterone, free testosterone, the free androgen index, or DHEA-S.
2. Ovulatory dysfunction. Cycles longer than 35 days, fewer than eight cycles a year, or absent cycles. A regular cycle does not always rule out anovulation; mid-luteal progesterone can confirm whether ovulation actually happens.
3. Polycystic ovarian morphology. On ultrasound, 20 or more follicles per ovary using a high-resolution probe, or ovarian volume of 8 mL or more. The 2023 Guideline added a validated AMH assay as an alternative to imaging.

Any two of the three is a diagnosis, once exclusions are ruled out. Order does not matter.

The piece most clinics miss: about 70 percent of cases meet two of three on cycle irregularity plus hyperandrogenism alone. In that majority, the third criterion (imaging or AMH) is not required for diagnosis. The Guideline is explicit on this. If a clinician is delaying your diagnosis pending an ultrasound and you already meet the cycle and hyperandrogenism criteria, the Monash plain-language summary of the Guideline can be pointed to directly.

Step 2: Know the exclusions

PMOS is, formally, a diagnosis of exclusion. Several other conditions cause overlapping symptoms and must be ruled out first. A workup that does not include these is incomplete:

• Thyroid dysfunction: TSH at minimum, sometimes free T4. Both hypo- and hyperthyroidism disrupt cycles.
• Hyperprolactinaemia: prolactin level. Elevated prolactin causes anovulation and clinically mimics PMOS.
• Non-classic congenital adrenal hyperplasia (NCAH): 17-hydroxyprogesterone, drawn on cycle day 3 to 5 in the early morning. NCAH affects roughly 1 in 200 women in some populations and presents almost identically to PMOS.
• Cushing’s syndrome and androgen-secreting tumours: considered when symptoms appear rapidly, when total testosterone is markedly elevated (two to three times the upper limit of normal or higher), or when other Cushing features are present.
• Hypogonadotropic hypogonadism: LH and FSH, particularly when the picture suggests low body weight, low body fat, or excessive exercise rather than PMOS.

If TSH, prolactin, and 17-OHP have not been ordered, the workup is not complete. This is worth flagging directly in the appointment.

Step 3: Ask for the right labs

For the androgen side of the workup, the labs that matter most are:

• Total testosterone, plus SHBG. Sex hormone-binding globulin (SHBG) drops with insulin resistance, which means free, biologically active testosterone can be elevated even when total testosterone reads as normal. Without SHBG, the free androgen index cannot be calculated, and the actual androgen burden is invisible. SHBG is one of the most informative single markers in a PMOS workup; it is also one of the most commonly left off.
• DHEA-S. The adrenal androgen marker. Useful for distinguishing ovarian from adrenal androgen sources.
• Free testosterone or free androgen index. Calculated from total testosterone and SHBG. This is the number that correlates best with clinical androgenic signs.

For the metabolic side, the 2023 Guideline recommends a 75-gram oral glucose tolerance test (OGTT) at diagnosis, ideally with insulin levels measured at fasting and at the two-hour mark. Fasting glucose alone misses early insulin resistance because the pancreas compensates by releasing more insulin while glucose stays in range. The mechanism is covered in depth in the insulin resistance pillar. HOMA-IR (calculated from fasting glucose and fasting insulin) is a useful supplement to the OGTT but is not a full substitute.

For the broader assessment, the 2023 Guideline added several screens that older PMOS workups often left out. These belong in the initial workup, not as later add-ons:

• Cardiometabolic: fasting lipid panel, blood pressure measurement, and the OGTT noted above. PMOS carries roughly a four-fold lifetime risk of type 2 diabetes and roughly a two-fold risk of cardiovascular disease, so the screening cadence (every one to three years depending on risk profile) reflects those numbers.
• Sleep apnoea: a symptom-based screen at diagnosis (snoring, witnessed apnoeas, daytime sleepiness, morning headaches) with a referral for a sleep study if symptoms warrant. Obstructive sleep apnoea is significantly more common in PMOS than in age-matched controls and is under-diagnosed at every body weight.
• Mental health: validated brief screens (PHQ-9 for depression, GAD-7 for anxiety) at diagnosis and periodically thereafter. Depression and anxiety prevalence in PMOS sits at roughly double the general-population baseline, and disordered eating is also elevated. Referral pathways belong on the plan, not as an afterthought.

Step 4: Know the AMH option

In the roughly 30 percent of cases where the third criterion does need to be assessed (regular cycles with hyperandrogenism, or irregular cycles without androgen findings), the 2023 Guideline added AMH as an alternative to imaging. This is a meaningful change.

A validated AMH assay is more specific than pelvic ultrasound for the granulosa-cell biology that drives PMOS. The most commonly cited platforms are the Roche Elecsys, Beckman Coulter Access 2, and Ansh AMH Gen II. The cutoff that suggests PMOS varies by assay. A reproductive endocrinologist or a clinician familiar with the 2023 Guideline should know which platform is in use and which cutoff applies.

AMH does not replace the rest of the workup; it replaces the imaging step where the third criterion is needed. AMH is also not a screening test in the general population: an isolated elevated AMH in someone without PMOS symptoms does not constitute a diagnosis.

Step 5: Know the adolescent rules

Under 18, the diagnostic rules tighten. Both hyperandrogenism and ovulatory dysfunction are required. Two of three is not enough. Ovarian morphology and AMH are explicitly not recommended for diagnosis in adolescents, because both findings are common in the general adolescent population and lead to false positives.

The first two years after menarche are a known window of physiological cycle irregularity. The current guidance, reinforced in the 2025 adolescent extension to the Guideline (Peña et al., BMC Medicine), is to consider a younger person at "increased risk of PMOS" and reassess at age 18, rather than locking in a diagnosis prematurely.

Step 6: If you have already been dismissed

Three patterns of dismissal show up most often. Knowing which one applies makes the next ask easier.

"Your labs are normal." Ask which labs were drawn. If only TSH and total testosterone, the workup is incomplete. The follow-up is whether SHBG, DHEA-S, 17-OHP, prolactin, and a 2-hour OGTT have been done. They usually have not.

"Your cycles are regular, so it is probably not PMOS." A regular cycle is not the same as ovulation. Mid-luteal progesterone (drawn around day 21 of a 28-day cycle, or seven days before the expected next period) confirms whether ovulation actually happened. Per the 2023 Guideline, a diagnosis can also be met with hyperandrogenism plus polycystic ovarian morphology in the presence of regular cycles.

"You are not overweight, so it is probably not PMOS." A substantial minority of people with PMOS sit at or below a BMI of 25. The 2026 Lancet rename consensus reports approximately 75 percent insulin resistance in lean PMOS. The full picture is in the pillar article on lean PMOS.

If a clinic has repeatedly missed the workup, asking for a referral to a reproductive endocrinologist or an endocrinologist with PMOS experience is a reasonable next step. The 2023 Guideline names healthcare-professional knowledge gaps explicitly as a recognised problem; it is not a personal failing.

What to bring to the next appointment

The components of a complete request, in one place:

Ask for the androgen panel:

• Total testosterone
• Free testosterone or the free androgen index
• SHBG
• DHEA-S

Ask for the exclusions:

• TSH
• Prolactin
• 17-hydroxyprogesterone

Ask for the metabolic workup:

• 75-gram oral glucose tolerance test with fasting and 2-hour insulin
• Fasting lipid panel
• Blood pressure measurement

Ask for the broader screens:

• Symptom-based sleep apnoea screen
• Validated mental health screens (PHQ-9, GAD-7)

Have ready:

• A cycle log covering at least the last three to six months (length, regularity, any tracked ovulation signs)
• Any prior lab results from this workup, especially androgens
• A list of androgenic features that are present and when they started
• Family history of PMOS, type 2 diabetes, cardiovascular disease, or thyroid conditions

A workup that includes the lists above is the version the 2023 Guideline describes. Anything substantially less is partial, and partial workups are how a two-year diagnostic delay becomes a four-year one.

If imaging or AMH is being weighed, ask explicitly whether your case requires the third criterion at all. About 70 percent of cases do not.

A regular period does not rule out PMOS. Normal fasting glucose does not rule out insulin resistance. An ultrasound alone does not make the diagnosis.